Brown & Brown is projected to report Q4 2025 earnings per share of $0.89, representing a 3.5% year-over-year increase, on revenue of approximately $1.65 billion, up 35.8% from the prior year’s quarter. This performance reflects strong net new and renewal business, higher organic revenue growth, an uptick in premium volume and improved investment income. Management has attributed the revenue surge to expanded cross-selling efforts across its wholesale and retail segments, as well as favorable market conditions in specialty lines.

In January 2026, Brown & Brown Healthcare was formally introduced as the firm’s National Healthcare Practice, consolidating more than 140 seasoned risk and insurance specialists. This initiative aims to provide tailored insurance solutions to hospitals, health systems and medical groups, supporting hundreds of clients with program design expected to underwrite billions of dollars in premiums globally. Early client engagements include group captive structures and value-based risk frameworks designed to contain medical inflation.

At its current valuation, Brown & Brown trades at a price-to-earnings ratio of 26.05 and a price-to-sales ratio of 5.04, while the enterprise-value-to-sales ratio stands at 6.31, reflecting investor confidence in the firm’s revenue growth trajectory. The balance sheet remains conservatively financed, with a debt-to-equity ratio of 0.64 and a current ratio of 1.18, indicating ample liquidity to support ongoing acquisitions and operational needs.

The board has approved a regular quarterly cash dividend of $0.165 per share, payable on February 11, 2026 to shareholders of record as of February 4, 2026. This marks the 26th consecutive year of dividend increases for Brown & Brown, underscoring its commitment to returning capital to shareholders and reflecting consistent cash flow generation from its brokerage and services businesses.